Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11886-020-01291-4 http://scihub22266oqcxt.onion/10.1007/s11886-020-01291-4 32291526!7154066!32291526     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Cardiol+Rep 2020 ; 22 (5): 31 Nephropedia Template TP {{tp|p=32291526|t=2020. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB |pdf=|usr=}}{{32291526}} gab.com Text Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB JO: Curr Cardiol Rep http://www.kidney.de/pget.php?&tw=1&pmid=32291526 #FOAvip PURPOSE OF REVIEW: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic. RECENT FINDINGS: Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated. Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change. Twit Text FOAVip Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB ????Curr Cardiol Rep http://www.kidney.de/pget.php?&tw=1&pmid=32291526 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32291526 #FOAvip English Wikipedia <ref>{{Cite pmid|32291526}}</ref> Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB #MMPMID32291526 Rico-Mesa JS; White A; Anderson AS Curr Cardiol Rep 2020[Apr]; 22 (5): 31 PMID32291526show ga PURPOSE OF REVIEW: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic. RECENT FINDINGS: Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated. Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change. |*Practice Guidelines as Topic[MESH] |Alveolar Epithelial Cells/*metabolism[MESH] |Angiotensin Receptor Antagonists/adverse effects/*therapeutic use[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Comorbidity[MESH] |Coronavirus Infections/*drug therapy/epidemiology[MESH] |Coronavirus/drug effects/*isolation & purification[MESH] |Diabetes Mellitus, Type 2/complications/epidemiology[MESH] |Humans[MESH] |Hypertension/complications/epidemiology[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/adverse effects/therapeutic use[MESH] |Pneumonia, Viral/*drug therapy/epidemiology[MESH]Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB (epmc).pdf DeepDyve Pubget Overpricing